Distinguished in Retinal Detachment

Matus Rehak

Giessen, HE, DE 
Distinguished in Retinal Detachment
Giessen, HE, DE 
OverviewLocationsClinical Research

Overview

Matus Rehak practices in Giessen, Germany. Mr. Rehak is rated as a Distinguished expert by MediFind in the treatment of Retinal Detachment. His top areas of expertise are Retinal Vein Occlusion, Mesenteric Venous Thrombosis, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Retinal Detachment.

Gender
Male

Locations

Giessen, HE, Germany
Other Locations
Leipzig, SN, Germany
Sachsen, BY, Germany
Berlin, BE 12200, Germany
St. Elisabeth Hospital
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Enrollment Status: Completed
Publish Date: December 03, 2018
Intervention Type: Drug
Study Phase: Phase 2

96 Total Publications

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.
Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.
Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Published: November 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rehak's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile